Founder-Led Biotech CSO Turnover: The Real Cause

Three CSOs in Four Years

Three Chief Scientific Officers in four years. Each one credible. Each one gone.

I’ve seen versions of this pattern often enough in founder-led biotech to treat it as a governance problem rather than a hiring problem.

The sequence usually looks the same. A founder-scientist recognizes that the company has grown beyond what they can personally direct. The board agrees. A search is launched. A strong candidate is hired, someone with drug-development judgment, scientific credibility, and the executive maturity the founder is said to be looking for.

A year later, that candidate resigns citing strategic differences. The board assumes the hire didn’t fit. Another search runs. Another exit follows. By the time the third CSO leaves, the board’s default conclusion is that the founder is bad at hiring.

That is one possible reading. It is usually the wrong one. The harder reading is that the company hasn’t yet decided what the CSO is actually authorized to do — because it hasn’t decided what the founder is still authorized to do.

Founder-led Biotech CSO: Two kinds of authority, one company

The unusual thing about a science-led company is that the founder does not simply hold organizational authority. They hold scientific authority. Those two things are not the same, and they don’t move at the same speed.

Organizational authority can move on an org chart in an afternoon. Titles change. Reporting lines redraw. Announcements go out.

Scientific credibility is a different kind of asset. It was built over years — in publications, in the platform the founder invented, in relationships with investigators, in the intuitions the rest of the laboratory has learned to trust. When the founder says they’re not sure about a compound, people in the building listen for reasons that have nothing to do with the org chart.

You can move decision rights on an org chart faster than you can move scientific credibility inside a laboratory.

That is the governance problem the CSO walks into. Not that the founder won’t let go, but that the company has appointed someone to hold formal scientific decision rights without deciding what happens to the informal scientific authority still resident in the founder.

If those two authorities align, no one notices. When they diverge — even quietly — the organization has to decide which one to follow.

Founder-Led Biotech CSO: The Founder’s Paradox in a laboratory

The behaviors that built the platform were once a survival requirement. In early biotech, the founder’s direct involvement in every consequential scientific call was often what protected the integrity of the science. There was no one else with the depth to make those calls, and the company would not exist without them.

That is different from being “unable to let go.” A founder-scientist may remain one of the most knowledgeable people in the building for years after the company outgrows their capacity to be the sole scientific decision-maker. The problem is not their scientific involvement. The problem is that continued involvement, undefined, functions as an unspoken authority the CSO is expected to work around.

The Founder’s Paradox applies here in a particularly hard form: the founder’s expertise remains legitimately valuable long after their authority needs to narrow.

Both things can be true. That is what makes the design work harder than it looks.

The bypass, and what actually goes wrong

Here is a version I’ve seen play out. A newly hired CSO reviews the data on a lead compound and decides to pause advancement into the next preclinical stage. The data doesn’t yet support it. The call is difficult, but it is within her mandate.

A senior researcher who has worked alongside the founder for a decade is unhappy with the decision. He walks into the founder’s office and asks for an opinion. The founder, acting on instinct, reviews the data and says he thinks the compound can move forward.

The founder disagreeing with the CSO is not the problem. Scientific disagreement inside a biotech is healthy, and suppressing founder input on the science could be disastrous — including for patient safety, data integrity, and capital deployment reasons that go well past ego.

The problem begins with what follows.

If the researcher goes back to the bench and continues advancing the compound. If resources quietly resume flowing. If the CSO’s decision is reversed in effect without ever being reversed in process. If the organization learns — informally, in the space of an afternoon — that the founder’s scientific view is where consequential decisions actually land.

That is the mechanism. Not the disagreement, but the absence of a defined path for resolving it. The founder never intended to override the CSO. He was behaving the way he always had, because no one had told him — and he had not told himself — what the new architecture actually required.

The CSO’s authority didn’t evaporate because of one comment. It evaporated because the organization had no protocol for what to do when the founder and the CSO reached different scientific conclusions, and the informal protocol filled the vacuum.

Accountability without authority

A CSO can be held accountable for pipeline quality, portfolio priorities, development milestones, and scientific talent while lacking authority over the decisions that actually determine those outcomes.

That mismatch is not sustainable. Not because senior executives will always leave when their authority is undermined — some absorb it, some renegotiate, some rebuild it slowly — but because the organization eventually notices which authority is real and behaves accordingly. The CSO’s departure is a lagging indicator. The authority erosion happened months earlier.

Before running another search, the useful question is not who to hire next. It is which decisions the next CSO will actually own, and which will remain with the founder, and what happens when the two of them disagree.

What the company should design before the next search

Any founder-led biotech hiring a CSO into a company where the founder remains involved should be able to answer, on paper, before the search:

Which scientific decisions belong to the CSO. Portfolio prioritization. Program go/no-go at defined stages. Resource allocation across programs. Scientific hires. External collaborations. The list can be tailored. It cannot be vague.

Which scientific decisions the founder retains. This may include the original platform thesis, particular research directions the founder is uniquely qualified to guide, board-facing scientific communication, or specific reserved veto rights on categories the company chooses to protect. Reserved rights are not undermining. Undefined rights are.

What the escalation path is when the two disagree. Whether it goes to the CEO (if the founder is not the CEO), to a scientific committee, to a specific board process, or to the founder as final arbiter on a defined subset of decisions. Any of these can work. What cannot work is “we’ll figure it out,” because when the disagreement actually happens, that phrase resolves toward whichever authority is stronger informally — which is usually the founder’s.

What the board’s role is when the structure gets tested. If the board treats founder–CSO disagreement as an executive matter to be worked out between them, the board has left the hardest part of the succession unresolved. If it treats disagreement as a governance question it is prepared to reinforce, the CSO has room to operate. That difference matters more than the specific candidate.

Whether the founder’s ongoing role has itself been designed. Scientific advisor, executive chair, active researcher on a specific program, board-facing scientific voice. Each of these produces a different authority architecture. Leaving it undefined is what allows the informal version to fill the space.

Look past the exit interview

When the third CSO leaves, the tempting move is to look at the resumes and conclude that the profile needs to change. Sometimes it does. Different stages of biotech legitimately require different leadership calibration, and a company preparing for clinical execution needs a CSO with different experience than a platform-formation company does.

But repeated turnover in the same seat, with different people, doing broadly the same job, is a signal worth reading before launching the same search again.

The next CSO does not need to be a better candidate than the last one. The seat needs to be a real one before they’re asked to sit in it.

Charlie Solorzano is Managing Partner at Alder Koten, where he works with boards, investors and leadership teams on life sciences executive search across the U.S. and Mexico. His work spans senior leadership and C-suite assignments in life sciences, healthcare and related sectors, with an emphasis on matching executive capability and calibration to the organization’s stage, operating environment and strategic mandate.